ALL patients with certain gene regulation patterns may be less likely to respond to CAR T-cell therapy

Share on facebook
Share on twitter
Share on linkedin
Share on email
Share on print

Acute lymphoblastic leukemia cells from patients whose cancers did not respond to CD19-targeted CAR T-cell therapy had gene regulation signatures that could potentially facilitate treatment resistance, according to results presented at the 2022 AACR annual meeting, April 8-13.

To access this subscriber-only content please log in or renew your subscription.

Looking for IP Login? Our IP Login system is now automatic. If your institution has a site license, please log in from on site or via your VPN to access this content.

Login Subscribe
Table of Contents

YOU MAY BE INTERESTED IN

Login